Patent Board Grants Inter Partes Review Of Arthritis Treatment Patent
(June 14, 2016, 1:15 PM EDT) -- ALEXANDRIA, Va. — A patented method of treating rheumatoid arthritis with anti-tumor necrosis factor α (anti-TNFα) combined with the anti-rheumatic drug methotrexate (MTX) is likely invalid, the Patent Trial and Appeal...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login